59718-83-1Relevant articles and documents
Macrocyclic Modulators of the Ghrelin Receptor
-
Paragraph 0411; 0414, (2018/05/03)
The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
Discovery of a new class of macrocyclic antagonists to the human motilin receptor
Marsault, Eric,Hoveyda, Hamid R.,Peterson, Mark L.,Saint-Louis, Carl,Landry, Annick,Vézina, Martin,Quellet, Luc,Wang, Zhigang,Ramaseshan, Mahesh,Beaubien, Sylvie,Benakli, Kamel,Beauchemin, Sophie,Déziel, Robert,Peeters, Théo,Fraser, Graeme L.
, p. 7190 - 7197 (2007/10/03)
A novel class of macrocyclic peptidomimetics was identified and optimized as potent antagonists to the human motilin receptor (hMOT-R). Well-defined structure-activity relationships allowed for rapid optimization of potency that eventually led to high aff